UOC
ARQT icon

UBS O'Connor’s Arcutis Biotherapeutics ARQT Stock Holding History

UBS O'Connor’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,201
Closed -$206K – 378
2025
Q1 		$206K Sell
13,201
-64,354
-83% -$907K ﹤0.01% 249
2024
Q4 		$1.08M Sell
77,555
-14,464
-16% -$158K 0.03% 222
2024
Q3 		$856K Buy
+92,019
New +$908K 0.02% 295
2022
Q3 		– Sell
-66,635
Closed -$1.42M – 962
2022
Q2 		$1.42M Buy
+66,635
New +$1.37M 0.01% 720

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return